SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global hemorrhagic shock treatment market is estimated to be valued at US$ 175.4 million in 2020 and is expected to exhibit a CAGR of 4.0% during the forecast period (2020-2027).
Key Trends and Analysis:
The global hemorrhagic shock treatment market is expected to witness significant growth owing to research & development activities and adoption of strategies such as collaborative licensing agreements. For instance, in January 2017, NuvOx Pharma LLC and Jiangsu Nhwa Pharmaceutical Co., Ltd. enter a collaborative licensing agreement to develop and sell NVX-408 in China for the treatment of hemorrhagic shock. The NVX-408 is an oxygen therapeutic that is injected intravenously and flows through the lungs and gathers oxygen. According to the pre-clinical studies, NVX408 can improve survival rate during severe blood loss.
In October 2019, scientists at the Feinstein Institutes for Medical Research completed a study that involves bio-electronic medicine strategies for the treatment of hemorrhagic shock (HS). The positive findings of the study have been published in the Springer Nature journal.
Key players in the hemorrhagic shock treatment market are focused on obtaining drug approvals and clearance from regulatory authorities to maintain a competitive edge in the market. For instance, in October 2019, the researchers at Feinstein Institutes for Medical Research conducted a study which proved the efficacy of bioelectric medicine for treatment of hemorrhagic shock. The study concluded that bioelectric medicine stimulates the nervous system and inhibits or modify the neural activity to better manage this condition.
Request for Sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/4097
Key Market Takeaways:
The global hemorrhagic shock treatment market is expected to exhibit a CAGR of 4.0% during the forecast period (2020-2027) owing to development of novel treatments for treatment of hemorrhagic shock.
North America is expected to be the most lucrative region in the global hemorrhagic shock treatment market due to the growing demand for disease-specific treatment, increasing focus on research & development, and rising number of FDA approvals for the treatment of hemorrhagic shock. For instance, in February 2017, the U.S. Army Institute of Surgical Research (USAISR) received FDA clearance for its hemorrhagic shock device.
Competitive Landscape:
Key players operating in the global hemorrhagic shock treatment market are Amneal Pharmaceuticals LLC, Biomedica Management Corporation, ZydusCadila, NuvOx Pharma LLC, Novartis AG, Leading BioSciences, Inc., Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Boehringer Ingelheim International GmbH, AstraZeneca, and Johnson & Johnson Services Inc.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4097
Market Segmentation:
-
Global Hemorrhagic Shock Treatment Market, By Drug:
- NVX-408
- YW-356
- LB-1148
- Neutrolide
- Others
-
Global Hemorrhagic Shock Treatment Market, By Distribution Channel:
- Retail Pharmacy
- Hospital Pharmacy
- Online Channels
-
Global Hemorrhagic Shock Treatment Market, By Region:
-
North America
- U.S.
- Canada
-
Europe
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
-
Asia Pacific
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
-
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
-
Middle East
- GCC
- Israel
- Rest of Middle East
-
Africa
- South Africa
- Central Africa
- North Africa
-
North America
Related Market Intelligence Report:
Ragweed Pollen Allergy Treatment Market, by Drug Class (Antihistamines, Decongestants, Nasal Corticosteroids, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Channel), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
Read more: https://www.coherentmarketinsights.com/market-insight/ragweed-pollen-allergy-treatment-market-4054
Tauopathies Treatment Market, by Disease (Frontoyemporal Degenration [Pick’s Disease, CBD, and PSP], Alzheimer’s Disease, and Other Neurodegenerative Diseases), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Sales), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
Read more: https://www.coherentmarketinsights.com/market-insight/tauopathies-treatment-market-3995
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
